Genetic risk score in patients with the APOE2/E2 genotype as a predictor of familial dysbetalipoproteinemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00084790" target="_blank" >RIV/00023001:_____/24:00084790 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/24:00135522 RIV/00216208:11110/24:10473360 RIV/00216208:11310/24:10473360 RIV/00159816:_____/24:00079479 RIV/00064165:_____/24:10473360

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S1933287423003422?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1933287423003422?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jacl.2023.11.010" target="_blank" >10.1016/j.jacl.2023.11.010</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Genetic risk score in patients with the APOE2/E2 genotype as a predictor of familial dysbetalipoproteinemia

Popis výsledku v původním jazyce

Background: Familial dysbetalipoproteinemia (FD) is an autosomal recessive (rarely dominant) inherited disorder that is almost exclusively associated with the apolipoprotein E gene (APOE) variability. Nonetheless, only a small proportion of APOE2/E2 subjects develop the phenotype for mixed dyslipidemia; the context of other trigger metabolic or genetic factors remains unknown. Methods: One hundred and one patients with FD and eighty controls (all APOE2/E2 homozygotes; rs429358) were screened for 18 single-nucleotide polymorphisms (SNPs) within the genes involved in triglyceride metabolism. Results: Two SNPs were significantly associated with the FD phenotype (rs439401 within APOE; P &lt; 0.0005 and rs964184 within ZPR1/APOA5/A4/C3/A1 gene cluster; P &lt; 0.0001). Unweighted genetic risk scores - from these two SNPs (GRS2), and, also, additional 13 SNPs with P-value below 0.9 (GRS15) - were created as an additional tool to improve the risk estimation of FD development in subjects with the APOE2/E2 genotype. Both GRS2 and GRS15 were significantly (P &lt; 0.0001) increased in patients and both GRSs discriminated almost identically between the groups (P = 0.86). Subjects with an unweighted GRS2 of three or more had an almost four-fold higher risk of FD development than other individuals (OR 3.58, CI: 1.78–7.18, P &lt; 0.0005). Conclusions: We identified several SNPs that are individual additive factors influencing FD development. The use of unweighted GRS2 is a simple and clinically relevant tool that further improves the prediction of FD in APOE2/E2 homozygotes with corresponding biochemical characteristics. © 2023

Název v anglickém jazyce

Genetic risk score in patients with the APOE2/E2 genotype as a predictor of familial dysbetalipoproteinemia

Popis výsledku anglicky

Background: Familial dysbetalipoproteinemia (FD) is an autosomal recessive (rarely dominant) inherited disorder that is almost exclusively associated with the apolipoprotein E gene (APOE) variability. Nonetheless, only a small proportion of APOE2/E2 subjects develop the phenotype for mixed dyslipidemia; the context of other trigger metabolic or genetic factors remains unknown. Methods: One hundred and one patients with FD and eighty controls (all APOE2/E2 homozygotes; rs429358) were screened for 18 single-nucleotide polymorphisms (SNPs) within the genes involved in triglyceride metabolism. Results: Two SNPs were significantly associated with the FD phenotype (rs439401 within APOE; P &lt; 0.0005 and rs964184 within ZPR1/APOA5/A4/C3/A1 gene cluster; P &lt; 0.0001). Unweighted genetic risk scores - from these two SNPs (GRS2), and, also, additional 13 SNPs with P-value below 0.9 (GRS15) - were created as an additional tool to improve the risk estimation of FD development in subjects with the APOE2/E2 genotype. Both GRS2 and GRS15 were significantly (P &lt; 0.0001) increased in patients and both GRSs discriminated almost identically between the groups (P = 0.86). Subjects with an unweighted GRS2 of three or more had an almost four-fold higher risk of FD development than other individuals (OR 3.58, CI: 1.78–7.18, P &lt; 0.0005). Conclusions: We identified several SNPs that are individual additive factors influencing FD development. The use of unweighted GRS2 is a simple and clinically relevant tool that further improves the prediction of FD in APOE2/E2 homozygotes with corresponding biochemical characteristics. © 2023

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

<a href="/cs/project/LX22NPO5104" target="_blank" >LX22NPO5104: Národní institut pro výzkum metabolických a kardiovaskulárních onemocnění</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of clinical lipidology

ISSN

1933-2874

e-ISSN

—

Svazek periodika

18

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

"e230"-"e237"

Kód UT WoS článku

001239945500003

EID výsledku v databázi Scopus

2-s2.0-85178638779